Screener
Twist Bioscience Corporation TWST Reportable Segment — Gain on sale of business
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Twist Bioscience Corporation in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnSaleOfBusiness.
The source filing: Twist Bioscience Corporation’s 10-K, filed November 17, 2025.
- Filed
- Nov 17, 2025
- Fiscal year
- FY2025
- Accession
- 0001581280-25-000025
| (In thousands) | Year ended September 30, 2025 | Year ended September 30, 2024 | Year ended September 30, 2023 |
|---|---|---|---|
| Impairment of long-lived assets | — | 44,930 | 6,785 |
| Total costs and expenses | $512,831 | $533,805 | $462,268 |
| Loss from operations | $(136,259) | $(220,831) | $(217,159) |
| Gain on sale of business | $48,847 | — | — |
| Interest income | 11,364 | 15,344 | 14,365 |
| Other income (expense), net | (903) | (2,679) | (672) |
| Income (loss) before income taxes | $(76,951) | $(208,166) | $(203,466) |
| Income tax expense | (719) | (560) | (1,152) |
Item 8. tatements and
FAQ
- What is Twist Bioscience Corporation's reportable segment — gain on sale of business?
- Twist Bioscience Corporation (TWST) reported reportable segment — gain on sale of business of $12.21M in Q3 2025.
- What does reportable segment — gain on sale of business mean?
- This metric records the profit realized from the divestiture or sale of a business unit or significant asset group within the reportable segment. It is a non-recurring item that provides a one-time boost to the segment's financial results. Investors monitor this to distinguish between gains from core operational growth and gains from capital allocation or portfolio optimization activities.
Ask your AI about Twist Bioscience Corporation's reportable segment — gain on sale of business.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude